Announcement Regarding the Clinical Study Report for SQ-22031 Eye Drops in Treating Neurotrophic Keratitis Phase II Clinical Trial

Shenyang Xingqi Pharmaceutical Co., Ltd.·July 8, 2026·2 pages

✨ AI Summary

Shenyang Xingqi Pharmaceutical announced the completion of the Phase II clinical study report for SQ-22031 eye drops for neurotrophic keratitis. The study demonstrated superior efficacy and good safety in the high-dose group, supporting its use as the proposed dose for Phase III trials. The results will not significantly impact recent earnings but highlight the long development cycle and market uncertainties for pharmaceutical products.

Summary generated by AI · Always verify with source document

Full Translation

AI Translation· gemini_document

Securities Code: 300573

Securities Abbreviation: Xingqi Eye Medicine

Announcement Number: 2026-035

Shenyang Xingqi Pharmaceutical Co., Ltd.

Announcement Regarding the Clinical Study Report for SQ-22031 Eye Drops in Treating Neurotrophic Keratitis Phase II Clinical Trial

The Company and all members of the Board of Directors guarantee the truthfulness, accuracy, and completeness of the information disclosed, and that there are no false records, misleading statements, or major omissions.

Shenyang Xingqi Pharmaceutical Co., Ltd. (hereinafter referred to as the "Company") announced today that it has obtained the clinical study report for the "Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Phase II Clinical Trial of SQ-22031 Eye Drops for the Treatment of Neurotrophic Keratitis (NK) Patients." In accordance with the "Shenzhen Stock Exchange Listed Company Self-Regulatory Guidelines No. 4 - GEM Industry Information Disclosure," the relevant content is hereby announced as follows:

I. Basic Information

Free accounts get 10 full releases per month. Pro subscribers get unlimited access.